Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective advertising.
Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective advertising. This story matters for Finance & Markets readers tracking trade. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. Trade-News curates and briefs the finance & markets stories that matter. Our editorial policy →